Marksans Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Marksans Pharma Limited Pharmaceutical Export Portfolio Dataset — 22 Products, $125.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Marksans Pharma Limited — Pharmaceutical Exporter Profile (2026) | 22 Products, $125.0M Trade | TransData Nexus

Product Portfolio — Top 22 by Export Value

Marksans Pharma Limited exports 22 pharmaceutical products across 11 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ibuprofen	Analgesics & Antipyretics	$53.8M	1,751	9.2%	4
2	Amino	Nutritional Supplements	$12.5M	540	3.9%	6
3	Gabapentin	CNS & Psychiatric	$9.1M	225	1.1%	15
4	Acetaminophen	Analgesics & Antipyretics	$8.7M	301	3.7%	4
5	Loratadine	Antihistamines & Allergy	$7.9M	339	4.6%	3
6	Cetirizine	Antihistamines & Allergy	$7.7M	338	4.3%	6
7	Paracetamol	Analgesics & Antipyretics	$6.3M	293	1.8%	10
8	Fluoxetine	CNS & Psychiatric	$5.6M	168	2.4%	7
9	Naproxen	Analgesics & Antipyretics	$5.1M	149	3.8%	8
10	Telmisartan	Cardiovascular	$1.4M	29	0.0%	13
11	Famotidine	Gastrointestinal	$1.2M	106	2.2%	11
12	Nifedipine	Cardiovascular	$949.0K	45	3.2%	8
13	Lisinopril	Cardiovascular	$936.1K	47	1.5%	8
14	Propranolol	Cardiovascular	$683.4K	28	1.2%	9
15	Roxithromycin	Advanced Antibiotics	$598.0K	15	14.3%	3
16	Terbinafine	Antifungals	$596.9K	27	2.2%	10
17	Guaifenesin	Respiratory & OTC	$576.5K	28	2.2%	9
18	Fluticasone	Respiratory	$290.0K	9	0.1%	13
19	Leflunomide	Immunosuppressants	$284.3K	11	1.9%	10
20	Isosorbide	Cardiovascular	$246.3K	14	0.5%	13
21	Imipenem	Advanced Antibiotics	$236.5K	8	0.7%	10
22	Docusate	Gastrointestinal	$102.5K	6	1.1%	9

Marksans Pharma Limited exports 22 pharmaceutical products across 11 therapeutic categories with a total export value of $125.0M. The top category is Analgesics & Antipyretics (59.2% of portfolio), followed by Antihistamines & Allergy (12.5%), indicating a concentrated portfolio with the top 5 products accounting for 73.7% of total export value.

Marksans Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Marksans Pharma Limited, established in 1992, is a prominent Indian pharmaceutical company specializing in the research, manufacturing, marketing, and sale of finished pharmaceutical formulations. Headquartered in Mumbai, Maharashtra, the company has expanded its global footprint, operating in over 50 countries and offering a diverse portfolio of over 300 products across 15 therapeutic areas.

The company's authorized share capital stands at ₹690 million, with a paid-up capital of ₹453.16 million. Marksans Pharma Limited is listed on the Bombay Stock Exchange (BSE) under the code 524404 and on the National Stock Exchange (NSE) under the symbol MARKSANS.

2Manufacturing Facilities

Marksans Pharma Limited operates state-of-the-art manufacturing facilities in North Goa, India; Verna, India; Farmingdale, USA; and Southport, UK. These facilities are approved by regulatory agencies such as the US FDA, UK MHRA, and Australian TGA, ensuring compliance with international quality standards.

3Key Leadership

The leadership team at Marksans Pharma Limited includes:

Mark B. Saldanha: Non-Independent Executive Chairman and Managing Director.

Jitendra M. Sharma: Group Chief Financial Officer.

Harshavardhan Panigrahi: Company Secretary, Manager of Legal and Compliance Officer.

Sandra Saldanha: Whole-Time Executive Non-Independent Director.

Varddhman Vikramaditya Jain: Whole-Time Executive Non-Independent Director.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Marksans Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Marksans Pharma Limited has a significant presence in regulated markets, including the United States, Europe, the United Kingdom, Australia, and New Zealand. The company's manufacturing facilities in the USA and UK have received approvals from the US FDA and UK MHRA, respectively, facilitating access to these markets.

In August 2025, Marksans Pharma Inc., a wholly owned subsidiary, received US FDA approval for Omeprazole Delayed-Release Tablets, 20 mg (OTC), demonstrating the company's commitment to expanding its product offerings in the US market.

2Emerging Markets

Marksans Pharma Limited has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards and regulatory approvals has enabled it to penetrate these markets effectively.

3Geographic Strategy

The company's geographic strategy focuses on diversification, reducing concentration risk by operating in over 50 countries. This approach allows Marksans Pharma Limited to mitigate market-specific risks and capitalize on growth opportunities across different regions.

Marksans Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Marksans Pharma Limited's wholly owned subsidiary, Time-Cap Laboratories, Inc., received an Establishment Inspection Report (EIR) from the US FDA for an audit conducted in October 2023, with no 483 observations issued during the audit.

In June 2020, the company voluntarily recalled Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, due to the detection of N-Nitrosodimethylamine (NDMA).

2WHO & EU GMP

Marksans Pharma Limited's manufacturing facilities have been approved by the World Health Organization (WHO) and hold European Union Good Manufacturing Practice (EU GMP) certificates, ensuring compliance with international quality standards.

3CDSCO & Indian Regulatory

Marksans Pharma Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained necessary approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its operations within India and for export purposes.

Marksans Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Marksans Pharma Limited faces competition from other pharmaceutical companies in overlapping therapeutic categories, including pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, and others. A detailed market share comparison and head-to-head analysis would require access to proprietary market research data.

2Key Differentiators

Marksans Pharma Limited's key differentiators include its extensive product portfolio, adherence to international quality standards, and a strong global presence. The company's manufacturing facilities are approved by regulatory agencies such as the US FDA, UK MHRA, and Australian TGA, ensuring compliance with stringent quality norms.

3Strategic Position

Marksans Pharma Limited's current strategic direction focuses on expanding its presence in regulated markets, enhancing its product portfolio, and strengthening its global footprint. The company's recent US FDA approval for Omeprazole Delayed-Release Tablets, 20 mg (OTC), reflects its commitment to growth in the US market.

Buyer Due Diligence Brief — Evaluating Marksans Pharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Marksans Pharma Limited has a track record of consistent export performance, with a total export value of $125.0 million USD and 4,477 shipments across 22 products in 11 therapeutic categories. The company's top five products—Ibuprofen, Amino, Gabapentin, Acetaminophen, and Loratadine—account for 73.7% of its export portfolio, indicating a focused approach in its product offerings.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirmed through the US FDA's Establishment Inspection Report (EIR) issued to Time-Cap Laboratories, Inc. in October 2023.

WHO-GMP Certification: Marksans Pharma Limited's manufacturing facilities are approved by the World Health Organization (WHO).

EU GMP Certification: The company's manufacturing facilities hold European Union Good Manufacturing Practice (EU GMP) certificates.

Frequently Asked Questions — Marksans Pharma Limited

How many pharmaceutical products does Marksans Pharma Limited export from India?

Marksans Pharma Limited exports 22 pharmaceutical products across 11 therapeutic categories. The top exports are Ibuprofen ($53.8M), Amino ($12.5M), Gabapentin ($9.1M), Acetaminophen ($8.7M), Loratadine ($7.9M). Total export value is $125.0M.

What is Marksans Pharma Limited's total pharmaceutical export value?

Marksans Pharma Limited's total pharmaceutical export value is $125.0M, based on 4,477 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Marksans Pharma Limited cover?

Marksans Pharma Limited exports across 11 therapeutic categories. The largest are Analgesics & Antipyretics (59.2%, 4 products), Antihistamines & Allergy (12.5%, 2 products), CNS & Psychiatric (11.8%, 2 products).

Get Full Marksans Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Marksans Pharma Limited

Marksans Pharma Limited — Export Portfolio & Destination Treemap

Who is Marksans Pharma Limited? — Company Overview & Market Position

What Does Marksans Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Marksans Pharma Limited Therapeutic Categories — 11 Specializations